ANI Pharmaceuticals (NASDAQ:ANIP) had its price target reduced by equities research analysts at Raymond James from $82.00 to $75.00 in a research note issued on Thursday, Stock Target Advisor reports. The brokerage presently has an “outperform” rating on the specialty pharmaceutical company’s stock. Raymond James’ price objective indicates a potential upside of 30.71% from the company’s previous close.
A number of other research firms have also recently weighed in on ANIP. Guggenheim initiated coverage on shares of ANI Pharmaceuticals in a research report on Thursday, September 12th. They issued a “buy” rating and a $76.00 price objective for the company. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. Finally, ValuEngine cut shares of ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $85.00.
Shares of ANIP stock traded down $4.05 on Thursday, reaching $57.38. 388,900 shares of the stock were exchanged, compared to its average volume of 137,916. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $73.65 and a two-hundred day moving average of $73.58. The stock has a market cap of $954.49 million, a P/E ratio of 12.45 and a beta of 2.20. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $86.96.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.20). The firm had revenue of $51.30 million during the quarter, compared to analysts’ expectations of $56.10 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.29 earnings per share. On average, equities research analysts predict that ANI Pharmaceuticals will post 5.29 EPS for the current fiscal year.
In other news, major shareholder Meridian Venture Partners Ii L sold 61,697 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $71.64, for a total transaction of $4,419,973.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 78,591 shares of company stock worth $5,582,839 in the last ninety days. Corporate insiders own 24.70% of the company’s stock.
Several hedge funds have recently modified their holdings of ANIP. Tower Research Capital LLC TRC bought a new position in ANI Pharmaceuticals in the second quarter worth about $32,000. Usca Ria LLC bought a new position in ANI Pharmaceuticals in the third quarter worth about $34,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ANI Pharmaceuticals by 237.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 559 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new position in ANI Pharmaceuticals in the third quarter worth about $92,000. Finally, Convergence Investment Partners LLC bought a new position in ANI Pharmaceuticals in the second quarter worth about $164,000. 70.97% of the stock is currently owned by institutional investors and hedge funds.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.